Printer Friendly

Eisai Announces Strategic Alliance With BioArctic Neuroscience To Develop Immunotherapy For Alzheimer's Disease.

Tokyo, Japan, Aug 26, 2005 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and BioArctic Neuroscience Inc. (Headquarter: Uppsala, Sweden, CEO: Par Gellerfors) announced today that on August 24, they signed a strategic alliance agreement to develop an immunotherapy for Alzheimer's disease. Based on this agreement, Eisai will obtain first right of refusal for drug candidates developed resulting from the research.

BioArctic Neuroscience Inc. is a biotech company that was established in January, 2003, with the aim of industrial application of Alzheimer's disease research by Prof. Lannfelt, Uppsala University, who is an internationally well-known Alzheimer's disease researcher.

Currently, Prof. Lannfelt's group is conducting basic research to further advance knowledge about the Arctic mutation of A, for immunotherapy in Alzheimer's disease. Arctic mutation of A is a mutation discovered by Prof. Lannfelt in 2001. It causes familial Alzheimer's disease and pathophysiologically shows very similar lesions to those found in non-familial Alzheimer's disease. In this respect, Arctic mutation of Ais expected to be applied to evaluate efficacy in a wide range of Alzheimer's disease treatment. The research will be carried out mainly by BioArctic Neuroscience and Prof. Lannfelt.

Eisai actively puruses alliances with outside organizations in order to expand its product line-up in the neurology arena, one of the company's franchise areas. With the BioArctic Neuroscience agreement, Eisai wishes to gain a new immunotherapy in drug treatment of Alzheimer's disease cut out by Aricept, and lead to a novel, beneficial treatment for Alzheimer's disease.


Copyright [c] 2005 JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCN Newswires
Geographic Code:9JAPA
Date:Aug 27, 2005
Previous Article:Regarding a Fire at Sanix Energy Tomakomai Power Plant.
Next Article:Showa Denko K.K. (SDK) Starts Production of 32-Inch Graphite Electrodes.

Related Articles
Brain goals for the 1990s.
Enzyme offers promise of Alzheimer's drugs.
Eisai Files Application Seeking Additional Indication for ARICEPT in US.
Eisai Resubmits Supplemental New Drug Application for Aricept, Alzheimers Disease Drug, to FDA.
Eisai Establishes European Strategic Business Hub in the U.K.
Dainippon Sumitomo Pharma and Eisai Sign Licensing Agreement for "Gasmotin", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members.
Eisai Pharmaceutical Marketing Subsidiary in Singapore Launches Operations.
Eisai Recieves Positive Opinion for Inovelon(R) Marketing Authorization from European Committee for Medicinal Products for Human Use (CHMP).
Eisai Announces Inovelon(R) Receives Marketing Authorization Approval from European Commission.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |